№ 5 / 2016 / 28-34

Clinical and pathogenetic relationship of coronary heart disease and osteoporosis

Author: Popova A.A.¹, Shilov S.N.², Berezikova E.N.³, Molokov A.V.⁴, Yakovleva I.V.⁵, Neupokoeva M.N.⁶, Teplyakov A.T.⁷, Grakova E.V.⁸, Kobets V.V.⁹

Author Affiliations

Abstract

It is shown that among the risk factors of osteoporosis and cardiovascular diseases caused by atherosclerosis revealed the following context: reduced bone mineral density was associated with arterial hypertension and hypertriglyceridemia; mineral density of the proximal femur inversely correlated with total cholesterol and atherogenic index. Increased production of proinflammatory cytokines and osteoprotegerin is important for the pathogenesis of osteoporosis and atherosclerosis. The common risk factors for cardiovascular disease and osteoporosis have been identified and can be used to form the high-risk groups for both diseases.

Key words

cytokines, atherosclerosis, bone mineral density, interleukin-1β, tumor necrosis factor-α, osteoprotegerin, osteoporosis

References

Berezikova E.N., Shilov S.N., Efremov A.V. et al. The role of cytokine aggression in the development of chronic heart failure / Kubanskiy nauchnyy medicinskiy vestnik=Kuban Scientific Medical Newsletter. 2011. (4) 29-31 [In Russian].
Men'shikova L.V., Khramtsova N.А., Yershova O.B. Outcomes of fractures of the proximal femur in the elderly and their health and social consequences / Nauchno-prakticheskaya revmatologiya=Scientific Practical Rheumatology. 2002. (4) 11-14. [In Russian]
Abedin M., Tintut Y., Demer L.L. Vascular calcification. Mechanisms and clinical ramifications // Arterioscler. Thromb. Vasc. Biol. 2004. ( 24) 1161-1170.
Bekker P.J., Holloway D., Nakanishi A. et al. The effect of a single dose of osteoprotegerin in postmenopausal women // J. Bone Miner. Res. 2001. (16) 348-360.
Bliuc D., Nguyen N.D., Milch V.E et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women // JAMA. 2009. (301) 513-521.
Bostrom К., Watson K.E., Hom S. et al. Bone morphogenic expression in human atherosclerotic lesions // J. Clin. Invest. 1993. (91) 1800–1809.
Bucay N., Sarosi I., Dunstan C.R. et al. Osteoprotegerindeficient mice develop early onset osteoporosis and arterial calcification // Genes Develop. 1998. (12) 1260-1268.
Center J.R., Nguyen T.V., Schneider D. et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study // Lancet. 1999. (353) 878-882.
Demer L.I. Vascular calcification and osteoporosis: inflammatory response to oxidized lipids // Int. J. Epidemio.l 2002. (31) 737-741.
Doherty T.M., Asotra K., Fitzpatrick L.A. et al. Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads // Proc. Natl. Acad. Sci. USA. 2003. (100) 11203-11206.
Frye M.A., Melton L.J., Bryant S.C. et al. Osteoporosis and calcification of the aorta // Bone Miner. 1992. (19) 185-194.
Fu M., Zhang J., Lin Y.Y. et al. Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in aortic smooth muscle cells // Biochem. Biophys. Res. Commun. 2002. (294) 597-601.
Hamerman D. Bone health across the generations. A primer for health providers concerned with osteoporosis prevention // Maturitas. 2004. (50) 1-7.
Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases // JAMA. 2004. 292 490-495.
Hofbauer L.C., Schoppet M. Editorial: Osteoprotegerin gene polymorphism and the risk of osteoporosis and vascular disease // J. Clin. Endocrinol. Metab. 2002. (87) 4078-4079.
Hofbauer L.C., Schoppet M. Osteoprotegerin: a link between osteoporosis and vascular calcification? // Lancet. 2001. (358) 257-259.
Horowitz M. Matrix proteins versus cytokines in the regulation of osteoblast function and bone formation // Calcif. Tissue Int. 2003. (72) 5-7.
Kang K. Low bone mineral density is associated with intracranial posterior circulation atherosclerosis in women // Bone. 2015. (81) 669-674.
Kiechl S., Schett G., Wenning G. et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease // Circulation. 2004. (109) 2175-2180.
Kiel D.P., Kauppila L.I., Cupples L.A. et al. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study // Calcif. Tissue Int. 2001. (68) 271-276.
Min H., Morony S., Sarosi I. et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis // J. Exp. Med. 2000. (192) 463-474.
Nakamura M., Udagawa N., Matsuura S. et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption // Endocrinology. 2003. (144) 5441-5449.
Parhami F., Morrow A.D., Balucan J. et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation of the paradox of arterial calcification in osteoporotic patients // Arterioscler. Thromb. Vasc. Biol. 1997. (17) 680-687.
Schoppet M., Preissner K.T., Hofbauer L.C. RANK ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function // Arterioscler. Thromb. Vasc. Biol. 2002. (22) 549-553.
Seo S.K., Yun B.H., Noe E.B. et al. Decreased bone mineral density is associated with coronary atherosclerosis in healthy postmenopausal women // Obstet. Gynecol. Sci. 2015. (58) 144-149.
Simonet W.S., Lacey D.L., Dunstan C.R. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density // Cell. 1997. (89) 309-319.
Whyte M.P., Obrecht S.E., Finnegan P.M. et al. Osteoprotegerin deficiency and juvenile Paget’s disease // N. Engl. J. Med. 2002. (347) 175-184.
Yano K., Tsuda E., Washida N. et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis // J. Bone Miner. Res. 1999. (14) 518-527.

About Authors (Correspondence):

Popova A.A. – doctor of medical sciences, head of the department of outpatient therapy and general medical practice, e-mail: ann24@ngs.ru

Shilov S.N. – doctor of medical sciences, assistant professor of the department of pathophysiology and clinical pathophysiology, e-mail: newsib54@gmail.com

Berezikova E.N. – doctor of medical sciences, assistant professor of the department of outpatient therapy and general medical practice, e-mail: berezikova@ngs.ru

Molokov A.V. – assistant of the department of outpatient therapy and general medical practice, e-mail: alex-molokov@mail.ru

Yakovleva I.V. – assistant of the department of outpatient therapy and general medical practice, e-mail: adrenalin21@mail.ru

Neupokoeva M.N. – assistant of the department of outpatient therapy and general medical practice, e-mail: maria.neupokoeva@mail.ru

Teplyakov A.T. – doctor of medical sciences, professor, head of department of heart failure

Grakova E.V. – doctor of medical sciences, senior researcher of the department of heart failure, e-mail: gev@cardio-tomsk.ru

Kobets V.V. – trauma surgeon of department of traumatology

Received: 08/11/2016